Clinical trial
Odiparcil QT Definitive Study
NCT00437242 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00437242 |
|---|---|
| Title | Odiparcil QT Definitive Study |
| Official title | A Study to Evaluate the Effect of Repeat Oral Doses of Odiparcil on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Fibrillation, Atrial, Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | Odiparcil |
| Enrollment | 54 |
| Start date | Oct 1, 2006 |
| First posted | Feb 19, 2007 |
| Last update posted | Jun 4, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: